Calamos Advisors LLC Purchases New Stake in Medpace Holdings Inc (MEDP)

Calamos Advisors LLC purchased a new stake in Medpace Holdings Inc (NASDAQ:MEDP) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 6,870 shares of the company’s stock, valued at approximately $412,000.

Several other large investors have also recently added to or reduced their stakes in the company. Granite Investment Partners LLC raised its position in shares of Medpace by 0.3% in the second quarter. Granite Investment Partners LLC now owns 260,447 shares of the company’s stock valued at $11,199,000 after purchasing an additional 864 shares during the period. Victory Capital Management Inc. raised its position in shares of Medpace by 15.9% in the second quarter. Victory Capital Management Inc. now owns 7,091 shares of the company’s stock valued at $305,000 after purchasing an additional 974 shares during the period. Metropolitan Life Insurance Co. NY raised its position in shares of Medpace by 57.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,144 shares of the company’s stock valued at $178,000 after purchasing an additional 1,507 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Medpace by 26.5% in the first quarter. The Manufacturers Life Insurance Company now owns 7,983 shares of the company’s stock valued at $278,000 after purchasing an additional 1,673 shares during the period. Finally, BlueMountain Capital Management LLC raised its position in shares of Medpace by 9.3% in the second quarter. BlueMountain Capital Management LLC now owns 21,710 shares of the company’s stock valued at $934,000 after purchasing an additional 1,848 shares during the period. 39.50% of the stock is currently owned by institutional investors.

A number of research firms have recently commented on MEDP. BidaskClub lowered shares of Medpace from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Zacks Investment Research raised shares of Medpace from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research report on Tuesday, July 3rd. SunTrust Banks began coverage on shares of Medpace in a research report on Monday, September 17th. They issued a “hold” rating and a $63.00 price target on the stock. Credit Suisse Group lifted their price target on shares of Medpace from $42.00 to $49.00 and gave the company an “outperform” rating in a research report on Tuesday, July 31st. Finally, William Blair raised shares of Medpace from a “market perform” rating to an “outperform” rating in a research report on Tuesday, July 31st. Five equities research analysts have rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the stock. Medpace currently has an average rating of “Buy” and an average price target of $46.57.



Shares of Medpace stock opened at $47.75 on Monday. The firm has a market capitalization of $1.70 billion, a PE ratio of 31.41, a P/E/G ratio of 1.22 and a beta of 1.02. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.68 and a current ratio of 0.68. Medpace Holdings Inc has a 1 year low of $31.70 and a 1 year high of $65.09.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Tuesday, July 31st. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.19. The business had revenue of $117.80 million for the quarter, compared to the consensus estimate of $104.97 million. Medpace had a net margin of 10.44% and a return on equity of 14.22%. Medpace’s quarterly revenue was up 24.5% on a year-over-year basis. During the same quarter last year, the company posted $0.38 earnings per share. On average, sell-side analysts anticipate that Medpace Holdings Inc will post 2.44 earnings per share for the current year.

In other news, CEO August J. Troendle sold 731,460 shares of the firm’s stock in a transaction on Monday, August 6th. The shares were sold at an average price of $59.26, for a total value of $43,346,319.60. Following the sale, the chief executive officer now owns 849,621 shares in the company, valued at $50,348,540.46. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Medpace Investors, Llc sold 2,713 shares of the firm’s stock in a transaction on Friday, September 21st. The stock was sold at an average price of $58.47, for a total transaction of $158,629.11. Following the completion of the sale, the insider now owns 9,027,814 shares in the company, valued at approximately $527,856,284.58. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,907,218 shares of company stock worth $656,554,339. 29.50% of the stock is currently owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Further Reading: Why Dividend Stocks May Be Right for You

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings Inc (NASDAQ:MEDP).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply